Abstract
A near-term market opportunity for cancer companion diagnostic tests exists in
drug selection for cancer therapy. Co-development of molecular diagnostics and
targeted therapeutics has already been proven to be a successful strategy in
the development of novel anti-cancer drugs. Adoption of biomarker development
in clinical research provides great opportunities to identify patient
subpopulations with differential drug responses and to uncover the underlying
mechanisms. These data could help to explain if clinical trials of new drugs
are adequate, and offer the possibility of creating a clear prescription path
based on predictive biomarkers. The purpose of this TriMark Publications
report is to describe the specific segment of the diagnostics market that
develops new technology platforms for evaluating the metabolism of therapeutic
agents, or for evaluating which therapeutic regimes are most effective for a
particular type of disease. The term companion diagnostic means that the
particular diagnostic test under evaluation is specifically linked to a known
therapeutic drug. This linkage could be important in the therapeutic
application and clinical outcome of a drug (personalized medicine), or an
important component of the drug development process. This report focuses on
the former linkage, i.e., the use of companion diagnostic tests in
personalized medicine.
View Cart
